MASCC Assessment Tools

©MASCC, Multinational Association for Supportive Care in Cancer™ •  All rights reserved worldwide.

 MASCC Antiemesis Tool © (MAT) 
The MASCC Antiemesis Tool© (MAT) was first created and posted in 2004. It is now available in several languages, obtained by the standard forward/backward translation process. The MAT was validated in 2007 by Molassiotis et al.* The MAT was developed by members of MASCC to assist patients and oncology professionals in communicating accurately about the prevention and control of nausea and vomiting associated with chemotherapy. The MAT provides a tool that is easy to use and evaluate, and that helps ensure the best patient care. Additionally, the tool can help treatment centers in understanding the effectiveness of antiemetic strategies.
The MAT is available in print and as an app at the App Store and Google Play

*Molassiotis A, Coventry PA, Stricker CT, Clements C, Eaby B, Velders L,Rittenberg C, Gralla RJ. Validation and psychometric assessment of a short clinical scale to measure chemotherapy-induced nausea and vomiting: the MASCC Antiemesis Tool. J Pain Symptom Manage. 2007 Aug; 34(2):148-159.

MASCC Oral Agent Teaching Tool © (MOATT)
The MASCC Oral Agent Teaching Tool© (MOATT) was developed by the MASCC Education Study Group to meet an identified need for healthcare providers involved in the education of patients receiving oral anticancer agents. The MOATT helps practitioners in providing comprehensive, standardized instruction. The MOATT provides a structured format to ensure that all key areas of patient assessment and teaching are addressed. It allows for individualization of teaching and uses evidence-based tenets in patient education. The MOATT has been cited in articles, used in research and quality improvement projects, and as an easy assist in patient education. The MOATT is both well researched and easy to use.

MASCC EGFR Inhibitor Skin Toxicity Tool © (MESTT)
The MASCC EGFR Inhibitor Skin Toxicity Tool© (MESTT) was developed by the MASCC Skin Toxicity Study Group in 2008. It is intended to assist oncology health professionals with the monitoring and reporting of dermatologic adverse effects in patients treated with epidermal growth factor receptor (EGFR) inhibitors. The MESTT is an event-specific grading system that can be used to standardize assessment, optimize the use of EGFR inhibitors, and enable researchers to conduct more informative, controlled studies in this patient population.

  • Caring for your skin, hair and nails on "Targeted Therapies" alt- Brochure for patients suffering with EGFRI side effects.
  • Clinical practice guidelines for the prevention and treatment of EGFR inhibitor-associated dermatologic toxicities- Supportive Care in Cancer, Volume 19

For more information contact us at [email protected]